Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 18,600 shares, a drop of 42.2% from the December 31st total of 32,200 shares. Based on an average daily volume of 31,600 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.6% of the shares of the company are sold short.

Artelo Biosciences Price Performance

Shares of ARTL stock traded up $0.01 on Thursday, hitting $1.19. 8,600 shares of the company’s stock were exchanged, compared to its average volume of 21,568. The company has a 50 day moving average of $1.10 and a 200 day moving average of $1.18. The stock has a market cap of $3.84 million, a P/E ratio of -0.41 and a beta of 1.25. Artelo Biosciences has a 12 month low of $0.91 and a 12 month high of $1.75.

Artelo Biosciences (NASDAQ:ARTL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06. Sell-side analysts predict that Artelo Biosciences will post -1.99 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. D. Boral Capital reissued a “buy” rating and set a $6.00 target price on shares of Artelo Biosciences in a report on Tuesday, January 14th. HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Artelo Biosciences in a report on Monday, December 9th. Finally, LADENBURG THALM/SH SH raised shares of Artelo Biosciences to a “strong-buy” rating in a report on Wednesday, December 25th.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.